GlassScriptPhysician profile
Matthew Kamin
NPI 1043203862
$30,794.66
in general payments reported to CMS, 2019-2025
34 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $582 · 2021: $1,455 · 2022: $2,362 · 2023: $2,500 · 2024: $7,632 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $8,006 · Travel and Lodging: $2,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,286.25 |
| Food and Beverage | $8,005.52 |
| Travel and Lodging | $2,226.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19,400.10 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,810.90 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $1,399.73 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $1,393.44 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,354.60 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $761.33 | 2019-2025 | Farxiga, Brilinta, Wainua |
| Boston Scientific Corporation | $656.52 | 2022-2025 | Watchman Access System |
| Pfizer INC. | $586.39 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $542.88 | 2022-2024 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $502.37 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $401.40 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lexicon Pharmaceuticals, INC. | $389.02 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $275.86 | 2020-2025 | Nexletol |
| Scpharmaceuticals INC. | $195.67 | 2023-2025 | |
| Amarin Pharma, INC. | $168.03 | 2020-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $162.38 | 2024 | Impella |
| Alnylam Pharmaceuticals INC. | $120.61 | 2025 | Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $112.20 | 2024 | Arcalyst |
| Abbott Laboratories | $99.42 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Inspire Medical Systems, INC. | $82.25 | 2023 | Inspire |
| Kowa Pharmaceuticals America, INC. | $62.06 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.80 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $34.54 | 2019 | |
| Ionis Pharmaceuticals, INC. | $31.86 | 2025 | Tryngolza |
| Biotronik INC. | $29.67 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $28.73 | 2019 | |
| Daiichi Sankyo INC. | $24.09 | 2023 | Injectafer |
| Lundbeck LLC | $19.73 | 2019 | |
| Mannkind Corporation | $18.77 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $16.32 | 2023 | Arcalyst |
| Mallinckrodt Hospital Products INC. | $15.80 | 2020 | |
| Astellas Pharma US INC | $15.63 | 2020 | |
| Mallinckrodt Enterprises LLC | $14.33 | 2019 | |
| Terumo Medical Corporation | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Kamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.